Skip to main content
Premium Trial:

Request an Annual Quote

Wendell Jones, Samraat Raha, Jim Slater, Mark Chandler, Walter Loewenbaum, Thomas Erickson, Mickey Urdea, Elena Grigorenko


Wendell Jones has joined Expression Analysis of Research Triangle Park, N.C., as a senior research statistician. Jones, who holds a PhD in mathematical sciences from Clemson University, previously worked for IBM as a senior software reliability engineer and as a manager of research and technology at Nortel Networks.

Samraat Raha has become chief business officer of Madison, Wis.-based EraGen. He joins the company from Incyte Genomics, where he was vice president of discovery services, including microarrays and bioreagents. Raha received a BA in molecular and cell biology from the University of California at Berkeley.

Jim Slater, executive chairman of investment company BioProjects International, has joined ViaLogy’s board of directors. BioProject International has been the lead investor of ViaLogy’s recent series A round. ViaLogy, a portfolio company of Viaspace Technologies, is developing technology to increase the detection sensitivity of DNA microarrays and other platforms.

Mark Chandler is planning to resign as president and CEO of Luminex in order to become chairman and CEO of a spinout the company is hoping to form of its Rules-Based Medicine unit (see story on page 1). While Chandler would remain a director of Luminex, Walter Loewenbaum would succeed him as chairman of the board of directors, and Thomas Erickson would join Luminex as interim president and CEO.

Mickey Urdea has been appointed to the board of directors of Quantum Dot, based in Hayward, Calif. Urdea is a founder of Chiron and a former senior vice president of nucleic acid diagnostics at Bayer. At Chiron, he developed branched DNA hybridization assays. After leaving Bayer, Urdea, who holds a PhD in biochemistry from Washington State University, became a biotechnology consultant for sev-eral firms.

Elena Grigorenko has joined the advisory board of NuGEN of San Carlos, Calif. She has been a researcher at Millennium Pharmaceuticals since 2000, where she has been responsible for projects that include microarray platform evaluations and RNA labeling improvements. Prior to that, Grigorenko was an instructor and assistant professor at the Wake Forest University school of medicine where she directed the molecular biology/microarray core facility. She holds a PhD in biochemistry from the Institute of Biological Physics of the Russian Academy of Sciences.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.